The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
India's pharmaceutical market (IPM) surged 10.1% year-on-year in March 2026, with anti-diabetic therapies leading at 15.5% growth thanks to generic semaglutide entries. The GLP-1 agonist segment exploded to Rs 15.8 billion in MAT March, nearly tripling YoY. Ind-Ra forecasts sustained 9-10% IPM growth in FY27 amid chronic therapy dominance.
With semaglutide's patent expired in India, over 50 generic brands are flooding the market at competitive prices, fueling a five-fold GLP-1 expansion to ₹5,000 crore by 2030. Startups like HealthifyRx, VLCC, Sugarfit, and FITPASS are redefining weight loss with holistic programs combining drugs, coaching, and muscle preservation. Investors warn that only comprehensive care models will thrive amid rising competition.
With GLP-1 drugs like semaglutide booming in India, dietitian Deepta Nagpall shares her exact daily meal plan to ensure adequate protein and fibre despite suppressed appetite. From omelettes to Greek yogurt, these nutrient-dense choices combat muscle loss and indigestion. Build sustainable habits for long-term success on weight loss medications.
A 32-year-old bride-to-be turned to Wegovy for wedding weight loss, only to face black tongue, unbearable stomach pain, and gallbladder removal. Sarah-Jayne Crawford's ordeal highlights hidden dangers of semaglutide injections. Despite initial success, severe side effects led to emergency surgery.
Many patients start GLP-1 medications like Ozempic and Zepbound for obesity but quit within a year, with fewer than one in four remaining on treatment. Shockingly, 74% of those who stop plan to restart, despite experts warning against this cycling approach. This guide explores the data, risks like muscle loss, and what it means for your health.
A large German study reveals that pairing GLP-1 receptor agonists with SGLT2 inhibitors significantly lowers all-cause mortality and cardiovascular risks in type 2 diabetes patients compared to SGLT2 inhibitors alone. Common combinations like dulaglutide plus empagliflozin showed a 29% mortality reduction. Experts highlight synergy but urge caution on potential harms.
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
Elon Musk's dramatic before and after photos have gone viral, spotlighting his slimmer appearance after confirming Mounjaro use. The Tesla CEO's 'Ozempic Santa' post ignited speculation on GLP-1 drugs' role in his 30-pound weight loss. Understand the science behind 'Mounjaro face' and real transformations.
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
